Quick Answer
Pacira BioSciences, Inc. reported Cash and Equivalents of $158.54 million for fiscal year 2025.
Pacira BioSciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $158.54M | -42.7% |
| 2024 | $276.77M | +80.5% |
| 2023 | $153.30M | +47.2% |
| 2022 | $104.14M | -82.2% |
| 2021 | $585.58M | +485.8% |
| 2020 | $99.96M | +27.8% |
| 2019 | $78.23M | -41.0% |
| 2018 | $132.53M | +144.8% |
| 2017 | $54.13M | +50.6% |
| 2016 | $35.94M | -36.9% |
| 2015 | $56.98M | +51.9% |
| 2014 | $37.52M | +199.8% |
| 2013 | $12.52M | +0.0% |
| 2012 | $12.52M | -72.9% |
| 2011 | $46.17M | +76.7% |
| 2010 | $26.13M | +269.3% |
| 2009 | $7.08M | -42.9% |
| 2008 | $12.39M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $147.59M | -40.0% | -50.9% |
| June 30, 2025 | $300.48M | +21.6% | +5.9% |
| March 31, 2025 | $283.61M | +54.1% | +2.5% |
| December 31, 2024 | $276.77M | +80.5% | +12.5% |
| September 30, 2024 | $245.97M | +148.2% | -0.4% |
| June 30, 2024 | $247.05M | +184.6% | +34.2% |
| March 31, 2024 | $184.05M | +417.8% | +20.1% |
| December 31, 2023 | $153.30M | +47.2% | +54.7% |
- Pacira BioSciences, Inc. showed a decrease of -42.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, Pacira BioSciences, Inc.’s cash and equivalents has grown by 1180.0% (from $12.39 million to $158.54 million).
- The most recent figure is from Pacira BioSciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: